Author

P. K. Reville

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Assay:scRNA-seq· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

K. Takahashi· 2 shared L. Wang· 2 shared M. R. Green· 2 shared N. Daver· 2 shared R. Wang· 2 shared A. C. Jain· 1 shared A. Choi· 1 shared A. Futreal· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

K. Takahashi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivSep 28, 2023

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor

W. C. Fiskus, J. Piel, M. Collins…·K. N. Bhalla

This study shows that FHD-286, a BRG1/BRM inhibitor, reduces AML burden and improves survival when combined with Menin or BET inhibitors in xenograft models of AML with MLL1r or mtNPM1.

DOI 10.1182/blood.2023022832

humanbulk RNA-seq

𝕏 PostBluesky

ImmunologybioRxivPreprintAug 28, 2023

CD8 T-cell dysfunction is linked with CAR T-cell failure and can be mitigated by a non-alpha IL-2 agonist, pegenzileukin

P. K. Reville, I. N. Sheikh, A. Choi…·M. R. Green

The paper identifies dysfunctional CD8 CAR T-cells in rrLBCL tumors and shows that pegenzileukin mitigates this dysfunction, improving CAR T-cell responses.

DOI 10.1101/2023.08.28.555127

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivSep 3, 2020

Single-cell Characterization of Acute Myeloid Leukemia and its Microenvironment Following PD-1 Blockade Based Therapy

H. A. Abbas, D. Hao, K. Tomczak…·A. Futreal

This study analyzes single-cell RNA and TCR profiles from AML patients before and after PD-1 blockade therapy to identify factors influencing response and resistance.

DOI 10.1038/s41467-021-26282-z

humanscRNA-seq

𝕏 PostBluesky